参考文献: 1.Bobillo S,et al. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. Haematologica. 2018 Feb;103(2):e92-e93. d...
临床中,中枢神经系统(CNS)复发是弥漫大B细胞淋巴瘤(DLBCL)最严重的并发症之一,中位生存不到1年。塞利尼索作为全球首个全新机制的口服选择性核输出蛋白抑制剂,临床研究显示,其可透过血脑屏障对中枢神经系统淋巴瘤具有抗肿瘤活性1,与靶向...
Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis, with a median overall survival of approximately five months [1]. The risk for CNS disease has been estimated to be about 5% overall [2], but it is significantly higher in ce...
87% of patients showed extranodal involvement outside the CNS. Patients generally had poor outcomes with a median overall survival (OS) of 3.4 months (95% CI 2.9–4.2) and a 2-year OS of 15% (10–22%). Outcomes did not differ depending on the site or time point of CNS events. ...
In addition to a high risk of systemic relapse, patients with DLBCL are at risk for progression of their lymphoma in the central nervous system (CNS). In the rituximab era, the rate and patterns of CNS involvement with DLBCL have evolved.12 The overall risk of CNS progression has been redu...
Conclusions: Patients with stage I DLBCL and EN disease have a worse outcome than those with nodal involvement. Late relapses are common, including CNS relapses, requiring prolonged surveillance. Patients with EN stage I DLBCL may benefit from RT consolidation and is deserving of further study. ...
Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients Jordyn Sava November 22nd 2024 Article Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia. ...
For example, if somebody has no evidence of marrow involvement on a PET scan or normal blood counts, I’ve taken to skipping the bone marrow biopsy on those folks. If they do have some suggestion of bone involvement or abnormal blood counts, I’ll do a bone marrow on those. Then if ...
At this year’s ASH, the controversy continued regarding how effective this strategy is in preventing CNS relapse. When we debate this, in patients who we may perceive to be high-risk by traditional measures, there are still some sites like testicular or adrenal involvement that are associated ...
Despite a large number of intermediate/high CNS-IPI patients, CNS recurrences were less than expected, suggesting a role of lenalidomide combination in decreasing the risk of CNS involvement. There is evidence that small molecules, such as lenalidomide, could cross the blood–brain barrier. Lenalidom...